Lupus

Should You Use Low Dose Naltrexone? A recent review of 105 studies and 15 randomized controlled trials of LDN found that, across a range of disorders (chronic pain, autoimmune and neuroimmune disorders, gastrointestinal disease, dermatological conditions, post-infectious https://t.co/sC7kteQVMZ

FDA has granted Fast Track designation to EG-501 (Evergreen), investigational Rx for cognitive impairment with neuropsychiatric systemic lupus erythematosus (NPSLE), following positive results from the phase 2 ClearMEMory study https://t.co/n9wO2wLLBk https://t.co/E0kL3j931Z

FDA Grants Fast Track Status to EG-501 in Neuropsychiatric Lupus | NeurologyLiv…

Joint Disease in SLE Reconsidered A new Frontiers in Immunology review from Ong, Wincup and colleagues, shows that lupus arthropathy is not a single uniform entity and it is biologically under-studied and clinically mismeasured, Moreover, the biology of lupus arthritis may https://t.co/M5m6TMZr3x

RheumNow Live 2027 registration is NOW OPEN. GLP-1s in your clinic. CAR-T in lupus. Rheumatology experts vs. AI, with your vote. Jan. 30–31 | Onsite + virtual Early Bird Pricing through 12/15/2026. See the agenda. Register: https://t.co/zYYC2350tE https://t.co/QeSxDPlIpv

RheumNow

RHEUMATOLOGIST Survey Q: How do you assess cutaneous lupus activity or treatment responses? CLICK HERE> https://t.co/PZDVpkqR1q https://t.co/bAQ7qNqGIA

Survey Result | RheumNow

Tis the Season for Vaccination Vaccination is essential for all rheumatologic patients, but particularly for patients on glucocorticoids and immunosuppression who face increased risk from infectious diseases. https://t.co/hHx1okkwHD https://t.co/nzRa9pzQ1X

‘Tis the Season for Vaccination | RheumNow

Novel Imaging of Skin Disease in Scleroderma An emerging technique called spatial frequency domain imaging (SFDI) proved its mettle for evaluating skin fibrosis in systemic sclerosis (SSc), also called scleroderma, in an early clinical study. https://t.co/vHmxD1cHRR https://t.co/BWW6Te9FFI

Novel Imaging of Skin Disease in Scleroderma | RheumNow

Article

van Vollenhoven’s Treatment Advances in Lupus

Jack Cush, MD Oct 22, 2026

Professor van Vollenhoven has compiled a state-of-the-art review on lupus treatment advances – current and future. SLE management is entering an unprecedented phase.

FDA has approved NDA for Evoxac, granting Cosette right to sell oral, liquid Evoxac as an alternative treatment option for managing dry mouth symptoms in Sjögren’s patients. NA until end of 2026. https://t.co/jTySNljXMv https://t.co/PCnfAmIB2W

Cosette lands FDA approval for Evoxac liquid in Sjögren’s disease

Portugese single center study of primary Sjögren’s dz shows early damage is assoc w/ 12-14X incr risk of lymphoma. 208 pts (F/U 14_ yrs) Damage seen in 79% & 85%. Mortality linked to age but not damage. 17 (8%) had lymphoma. Early damage incr lymphoma (HR 14.5 or HR https://t.co/g62KtjDuWg

RheumNow Live 2027 registration is NOW OPEN. GLP-1s in your clinic. CAR-T in lupus. Rheumatology experts vs. AI, with your vote. Jan. 30–31 | Onsite + virtual Early Bird Pricing through 12/15/2026. See the agenda. Register: https://t.co/zYYC2350tE https://t.co/mPdcOhbrC6

RheumNow

Article

Novel Imaging of Skin Disease in Scleroderma

MedPage Today Oct 20, 2026

An emerging technique called spatial frequency domain imaging (SFDI) proved its mettle for evaluating skin fibrosis in systemic sclerosis (SSc), also called scleroderma, in an early clinical study.

FDA has granted Fast Track designation to EG-501 (Evergreen), investigational Rx for cognitive impairment with neuropsychiatric systemic lupus erythematosus (NPSLE), following positive results from the phase 2 ClearMEMory study https://t.co/n9wO2wLLBk https://t.co/Vejldj5PlQ

FDA Grants Fast Track Status to EG-501 in Neuropsychiatric Lupus | NeurologyLiv…

Thai study of opportunistic infx in Pediatric SLE - 177 pSLE, & 38 developed OI (3.4/100PY). Most common OIs: Candida (27%), Aspergillus (13.5%), CMV (13.5%) - lung & skin mostly. Risk factors: Pulse steroids, Dz activity (SLEDAI-2K ≥11) https://t.co/0zjDOnDCEh https://t.co/H7JZ56ItDY

Characteristics and associated risk factors of opportunistic infection in child…

Should You Use Low Dose Naltrexone? A recent review of 105 studies and 15 randomized controlled trials of LDN found that, across a range of disorders (chronic pain, autoimmune and neuroimmune disorders, gastrointestinal disease, dermatological conditions, post-infectious https://t.co/lmjJoGlFAZ

Article

Joint Disease in SLE Reconsidered

Jack Cush, MD Oct 19, 2026

A new Frontiers in Immunology review from Ong, Wincup and colleagues, shows that lupus arthropathy is not a single uniform entity and it is biologically under-studied and clinically mismeasured, Moreover, the biology of lupus arthritis may shed light on choosing the best therapy for MSK

RHEUM SURVEY>> How do you assess cutaneous lupus activity or treatment responses? Click here>> https://t.co/1HWC4DV55h https://t.co/X8MUqjxqys

Cutaneous Lupus Challenges | RheumNow

Article

‘Tis the Season for Vaccination

Eric Dein, MD Oct 19, 2026

As the leaves start changing color and spooky decorations populate neighborhood doorsteps, another autumnal tradition begins: vaccination counseling. Fall offers a golden opportunity to protect our patients before respiratory viruses fill our waiting rooms. In patients with rheumatologic

92 early (<2 yrs) systemic sclerosis pts were treated with #MTX; 79% diffuse SSc. At 3 mos, 34% of dcSSc ≥25% reduction in mRSS - increasing to 612% a@ 24 mos (29% at 24 mos ITT w/ non-responder imputation). GC did not improve skin. Dz progression seen w/ 75% of MTX monoTx D/C https://t.co/w5Gc3ntej0

Univ Toronto lupus clinic study of 165 #SLE pts w/ Bx-proven LN (age 35.3 yrs; Dz dur 6.2 years). Half on antimalarial Rx. Being on HCQ did not alter Renal Bx outcomes (prolif GN, NIH AI, NIH CI, IFTA score. (But is known to improve renal outcomes) https://t.co/oQ0CgK7rXm https://t.co/PZX31wOPmL

Antimalarial exposure and renal histopathologic findings in lupus nephritis

Article

Troubles with ‘Gut Feelings’ (10.16.2026)

Jack Cush, MD Oct 16, 2026

Dr. Jack Cush reviews this week's news from RheumNow.com, including: placebo trumps controversial therapies, the dynamics of disease activity, fuse the big toe, and patients don’t appreciate being told “it's all in your head”!

92 early (<2 yrs) systemic sclerosis pts were treated with #MTX; 79% diffuse SSc. At 3 mos, 34% of dcSSc ≥25% reduction in mRSS - increasing to 612% a@ 24 mos (29% at 24 mos ITT w/ non-responder imputation). GC did not improve skin. Dz progression seen w/ 75% of MTX monoTx D/C https://t.co/WvqyI8GKjT

EADV abstract showed daxdilimab (anti-ILT7; on plasmacytoid dendritic cells) was effective in mod-severe discoid lupus. Ph II RCT 72 refract. DLE RCT; DAX vs PBO - ↓ CLASI-A vs placebo @24 wks. wk 4 ≥50% CLASI-A ~62% vs 24% https://t.co/gJ4drxErGD https://t.co/TexG55dDBL

In Phase 2 Trial, Daxdilimab Reduces Disease Activity in Moderate-to-Severe Dis…

Univ Toronto lupus clinic study of 165 #SLE pts w/ Bx-proven LN (age 35.3 yrs; Dz dur 6.2 years). Half on antimalarial Rx. Being on HCQ did not alter Renal Bx outcomes (prolif GN, NIH AI, NIH CI, IFTA score. (But is known to improve renal outcomes) https://t.co/oQ0CgK7rXm https://t.co/cJMMVFmLcy

Antimalarial exposure and renal histopathologic findings in lupus nephritis

? value of FamHx in Rheum evals? My bias is that few Dz are heritable - #Ank Spondylitis, #gout, DIP Osteoarthritis! But literature says there's high heritability for SLE, RA, systemic sclerosis, Sjögren's, & autoimmune endocrinopathies. WHAT do you think? https://t.co/WGyQqpY1qX